Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901
Naoto Morikawa(Tohoku University), Toshihiro Nukiwa(Tohoku University), Akira Inoue(Tohoku University Hospital), Toshiyuki Harada(Hokkaido hospital), Hiroshi Yokouchi(National Hospital Organization Hokkaido Medical Center), Hiroshi Watanabe(Tohoku University), Mariko Kanbe, Shunichi Sugawara(Sendai Kousei Hospital), Kazuhiro Usui(Hokkaido University Hospital), Toshiro Suzuki(Sendai Kousei Hospital), Yuka Fujita, Hiroki Nagai(Kyoto University), Terufumi Katoh(Kanagawa Prefectural Hospital Organization), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Masao Harada(Shikoku Cancer Center), Jun Sakakibara‐Konishi(Hokkaido University)
Cited by 9
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953